Biocad targets entry to Europe with Finnish project

25 May 2017

Leading Russian biotech firm Biocad is to expand its operations into Finland as the company sets its sights on European markets.

Biocad is to spend more than 25 million euros ($28 million) over seven years on collaborations with Finnish research and educational organizations, as well as on commercial manufacturing, in an agreement signed this week (as pictured above, with Biocad CEO Dmitry Morozov the second-from-right).

The first of its European facilities and collaborative scientific projects will be located in Turku, which is in the south west of the country and is home to one of Europe’s major biopharmaceutical clusters.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK